Unknown

Dataset Information

0

Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy.


ABSTRACT: Insulin resistance associated disorders (IRAD), including prediabetes, type 2 diabetes mellitus (T2DM), and fatty liver are significant risk factors of liver-related death in chronic hepatitis B (CHB). However, their relationship remains unclear. We aimed to evaluate how IRAD influence the kinetics of serum hepatitis B surface antigen (HBsAg) in patients with CHB during long-term entecavir treatment. We enrolled 140 patients with CHB receiving at least 3 years of consecutive entecavir treatment in this retrospective study. A linear mixed effects model was adopted to examine the effects of variables and their interaction over time on the HBsAg trajectory. Furthermore, we acquired cytokine profiles and baseline fibrosis-4 index (FIB-4) scores for in-depth analysis. The median treatment time was 6.90 (4.47-9.01) years. Multivariate analysis revealed that older patients or those with prediabetes or T2DM had a significantly slower HBsAg decline over time (p = 0.0001 and p < 0.0001, respectively). Conversely, advanced fatty liver engendered a more rapid HBsAg decrease (p = 0.001). Patients with prediabetes or T2DM possessed higher IP-10 levels six years after entecavir therapy (p = 0.013). Compared to patients without prediabetes or T2DM, diabetic patients had more unfavorable features at the baseline, especially higher FIB-4 scores. Prediabetes or T2DM delays the clearance of HBsAg, but advanced hepatic fatty change counterbalances the effect. Additionally, IRAD could cause hepatic sequelae in CHB through immune-metabolic pathways.

SUBMITTER: Lin TC 

PROVIDER: S-EPMC6912775 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy.

Lin Tien-Ching TC   Liu Wen-Chun WC   Hsu Yu-Hsiang YH   Lin Jia-Jhen JJ   Chiu Yen-Cheng YC   Chiu Hung-Chih HC   Cheng Pin-Nan PN   Chen Chiung-Yu CY   Chang Ting-Tsung TT   Wu I-Chin IC  

Journal of clinical medicine 20191106 11


Insulin resistance associated disorders (IRAD), including prediabetes, type 2 diabetes mellitus (T2DM), and fatty liver are significant risk factors of liver-related death in chronic hepatitis B (CHB). However, their relationship remains unclear. We aimed to evaluate how IRAD influence the kinetics of serum hepatitis B surface antigen (HBsAg) in patients with CHB during long-term entecavir treatment. We enrolled 140 patients with CHB receiving at least 3 years of consecutive entecavir treatment  ...[more]

Similar Datasets

| S-EPMC5318891 | biostudies-literature
| S-EPMC4468690 | biostudies-literature
| S-EPMC6590282 | biostudies-literature
| S-EPMC7809351 | biostudies-literature
| S-EPMC9736898 | biostudies-literature
| S-EPMC9845664 | biostudies-literature
| S-EPMC3371426 | biostudies-literature
| S-EPMC4491974 | biostudies-literature
| S-EPMC7839551 | biostudies-literature
| S-EPMC7096224 | biostudies-literature